Secukinumab IL-17A receptor interaction: what evidence supports downstream cytokine reduction?

Evidence supporting downstream cytokine reduction includes rapid temporal correlation between IL-17A neutralization and suppression of IL-17-dependent mediators, quantitative reductions in cytokines and inflammatory biomarkers, pathway-specific effects with preserved immune function, cellular changes including neutrophil clearance and tissue normalization, and dose-response relationships, though most studies infer receptor interaction from downstream effects rather than measuring direct binding.

Abstract

Secukinumab, a fully human monoclonal antibody, selectively binds and neutralizes IL-17A, with target engagement demonstrated through accumulation of total IL-17A and decreased free IL-17A levels following treatment. Evidence supporting downstream cytokine reduction includes rapid suppression of the IL-23/IL-17 axis beginning at Week 1, with concurrent reductions in IL-17-dependent mediators including beta-defensin2, CXCL1, and CXCL8. Quantitative reductions include IL-6 decreases up to 38.4%, CRP reductions of 35.3%, and IL-17A declines of 42-68% over 52 weeks, with effects sustained for at least one year. The temporal correlation between IL-17A suppression at Week 4 and clinical/histological responses at Week 12, combined with pathway-specific effects (limited TNF-α modulation despite robust IL-17-dependent mediator reduction), establishes a causal link rather than simple correlation. Cellular evidence includes rapid neutrophil clearance, normalization of keratinocyte function, and histological resolution of tissue pathology.

However, most studies infer receptor interaction from downstream effects rather than measuring direct receptor binding or occupancy. The mechanistic sequence—from IL-17A binding through immediate pathway suppression to cytokine reduction and clinical improvement—is supported by dose-response relationships and preserved immune function (maintained T-cell activation and microbial response capacity). The evidence strongly supports that secukinumab’s IL-17A neutralization directly causes downstream cytokine reduction through selective pathway inhibition, though direct receptor binding studies would strengthen mechanistic understanding.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. Records from Elicit search.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.

Screening

We screened in sources based on their abstracts that met these criteria:

• Human Participants with Secukinumab: Does this study involve human participants who were treated with secukinumab?
• Cytokine/Inflammatory Marker Measurement: Does this study measure cytokine levels, inflammatory markers, or downstream inflammatory mediators?
• Comparative or Longitudinal Design: Does this study include pre- and post-treatment measurements or comparison groups to assess treatment effects?
• Appropriate Patient Population: Does this study include patients with inflammatory conditions where secukinumab is clinically indicated?
• Acceptable Study Design: Is this study a randomized controlled trial, observational study, systematic review, or meta-analysis?
• Human Study Focus: Does this study include human data?
• Secukinumab Inclusion: Does this study include secukinumab treatment?
• Adequate Sample Size: Does this study include 10 or more participants?

We considered all screening questions together and made a holistic judgment about whether to screen in each paper.

Data extraction

We asked a large language model to extract each data column below from each paper:

• Study Type: Extract the type of study and level of evidence provided for secukinumab IL-17A receptor interaction and downstream cytokine effects.
• IL-17A Mechanism: Extract all evidence describing how secukinumab interacts with IL-17A and its receptor.
• Downstream Cytokines: Extract comprehensive data on cytokine reduction following secukinumab treatment.
• Evidence Linking: Extract evidence that links secukinumab’s IL-17A receptor interaction to observed downstream cytokine reductions.
• Timeline Effects: Extract detailed timeline of when downstream cytokine reduction occurs relative to secukinumab administration.
• Supporting Biology: Extract additional biological evidence that supports the IL-17A receptor-mediated cytokine reduction mechanism.

Results

Characteristics of Included Studies

The systematic review identified 10 studies evaluating secukinumab’s mechanism of action and downstream effects on cytokine reduction.

Evidence of IL-17A Receptor Interaction

Studies evaluated secukinumab’s mechanism through multiple approaches, though most inferred receptor interaction from downstream effects rather than measuring direct binding. Secukinumab is described as a fully human monoclonal antibody that selectively inhibits IL-17A and binds to human IL-17A, neutralizing its bioactivity. The mechanism involves direct neutralization of IL-17A’s biological activity, preventing IL-17A from binding to its receptor and triggering downstream inflammatory cascades.

Downstream Cytokine and Biomarker Reduction

Studies documented comprehensive reductions in inflammatory mediators following secukinumab treatment, though the specific cytokines measured and measurement approaches varied across investigations.

Temporal Correlation Between IL-17A Inhibition and Cytokine Reduction

The timeline of cytokine reduction following secukinumab administration showed remarkably early and sustained effects across multiple studies.

Supporting Biological Evidence

Beyond cytokine measurements, multiple studies documented cellular, histological, and functional changes supporting the IL-17A receptor-mediated mechanism.